AG957

AG957 (Tyrphostin AG957; NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity[1][2]. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity[3].

Product Specifications

CAS Number

[140674-76-6]

Product Name Alternative

Tyrphostin AG957; NSC 654705

UNSPSC

12352005

Target

Bcr-Abl

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ag957.html

Purity

99.30

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(C=C(C=C1)O)CNC2=CC=C(C=C2)C(OC)=O

Molecular Formula

C15H15NO4

Molecular Weight

273.28

References & Citations

[1]G Kaur, et al. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994 Apr;5 (2) :213-22.|[2]R Bhatia, et al. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia. 1998 Nov;12 (11) :1708-17.|[3]P A Svingen, et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res. 2000 Jan;6 (1) :237-49.|[4]Panfeng Fu, et al. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308 (10) :L1025-38.